慢性肢体威胁性缺血患者股腘动脉药物涂层球囊或支架干预后的临床结局
多中心回顾性观察研究纳入日本21个中心的900例慢性肢体威胁性缺血(CLTI)患者,比较初次股腘动脉(SFA)血管内治疗使用药物涂层球囊(DCB,n=458)或支架(n=442)的临床结局。经倾向评分逆概率加权后,DCB组主要不良肢体事件(MALE)风险低于支架组,风险比0.68(95%CI 0.52-0.89;P=.005)。DCB组术后慢血流发生率较高、急性闭塞发生率较低(Bonferroni校正后均P<.005)。
要点
- DCB组MALE风险低于支架组,HR 0.68(95%CI 0.52-0.89;P=.005)。
- DCB组术后慢血流发生率高于支架组,Bonferroni校正后P<.005。
- DCB组急性闭塞发生率低于支架组,Bonferroni校正后P<.005。
核心结论
- DCB血管成形术的MALE风险低于支架置入;这些结果提示DCB在CLTI患者初次SFA干预中可能更有益。
研究设计与样本
- 多中心回顾性观察研究,在日本21个中心开展,纳入900例接受初次SFA血管内治疗的CLTI病例,DCB组n=458、支架组n=442,中位随访17.5个月(四分位距6.2-31.9个月)。
- 采用倾向评分逆概率加权控制潜在混杂(患者人口学、合并症、用药及操作细节),主要结局采用病因别风险模型(Fine和Gray比例风险模型,死亡作为竞争风险)。
主要发现
- DCB组MALE风险低于支架组,风险比0.68(95%CI 0.52-0.89;P=.005)。
- DCB组术后慢血流发生率高于支架组,Bonferroni校正后P<.005。
- DCB组急性闭塞发生率低于支架组,Bonferroni校正后P<.005。
关键数值与推荐
- 主要结局为MALE;次要结局包括技术成功、慢血流、30天内死亡、30天内主要不良事件、再狭窄、靶病变血运重建、急性闭塞、创面愈合、大截肢和全因死亡。
临床怎么用
- 作者认为,这些结果提示DCB在CLTI患者初次SFA干预中可能更有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular treatment (EVT) for patients with an occlusive lesion of the femoropopliteal artery is performed worldwide due to its effectiveness. However, lesions in chronic limb-threatening ischemia (CLTI) are complex and a major concern in superficial femoral artery (SFA) EVT. Despite this, a detailed study of SFA EVT, and especially selection of the final device as a drug-coated balloon (DCB) or a stent, has not been performed in patients with CLTI. The aim of this stud was to compare the clinical outcomes of SFA EVT using a DCB or a stent in patients with CLTI. METHODS: A multicenter retrospective observational study was performed at 21 Japanese centers. Comparisons were made between patients undergoing initial SFA EVT with a DCB or stenting after inverse probability of treatment weighting using the propensity score to control for potential confounding (patient demographics, comorbidities, medications, and procedural details). The primary outcome measure was major adverse limb events (MALE). We adopted cause-specific hazard models, using Fine and Gray's proportional hazards model in which death was treated as a competing risk. Secondary outcome measures were also evaluated: (1) technical success; (2) slow flow; (3) death within 30 days; (4) major adverse events within 30 days; (5) restenosis; (6) target lesion revascularization; (7) acute occlusion; (8) wound healing; (9) major amputation; and (10) all-cause mortality. RESULTS: The study included 900 CLTI cases that underwent EVT with a DCB (n = 458) or stenting (n = 442) and had a median follow-up period of 17.5 months (interquartile range, 6.2-31.9 months). The DCB group had a lower risk of MALE than the stent group, with a hazard ratio of 0.68 (95% confidence interval, 0.52-0.89; P = .005). Subsequent analysis for the secondary outcome measures demonstrated that the DCB group had a higher prevalence of postprocedural slow flow and a lower incidence rate of acute occlusion (both P < .005 after Bonferroni correction). CONCLUSIONS: DCB angioplasty had a lower risk of MALE than stenting. These results suggest that a DCB might be more beneficial in initial SFA intervention in patients with CLTI.
引用
- Kobayashi T, Takahara M, Fujimura N, et al. Clinical outcomes in patients with chronic limb-threatening ischemia after femoropopliteal intervention with a drug-coated balloon or stenting. J Vasc Surg. 2025. PMID: 39978489. doi:10.1016/j.jvs.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。